Research to end asbestos-related cancer

May 16, 2013
Asbestos hazard. Credit: Shutterstock

Scientists from Flinders University are trying to develop a new treatment for a highly aggressive, asbestos-related lung cancer that is set to become more prevalent in the future.

Led by Associate Professor Sonja Klebe, the researchers are testing a combination of drugs and to block two proteins that help stimulate the growth of mesothelioma – a deadly tumour that develops on the surface lining of the lungs from exposure to airborne .

Australia has the highest incidence of mesothelioma in the world, with about 700 new cases each year, due to the country's long history of asbestos use, particularly in the construction industry, between 1945 and 1980.

Although asbestos is now banned, the disease is expected to peak to about 900 annual cases in Australia by 2020 because of the nation's continued exposure to buildings containing asbestos and the latency of the disease, which can take years to develop.

Associate Professor Klebe said the team were trying to target a growth factor and a that promote tumour growth directly and/or help grow the that feed the tumour.

"In order for the to grow it needs nutrients from the blood so it secretes these proteins and they signal for blood vessels to grow," Associate Professor Klebe, based in the Department of Anatomical Pathology at Flinders Medical Centre, said.

"We know that blocking alone can delay the progression of and so does blocking alone but no one knows what happens when you block them together," she said.

"There's no cure for mesothelioma and the only treatment besides chemotherapy is aggressive surgery that strips the lining of the rib cage and removes the lung, providing only one lung has been affected, so hopefully we can offer a much less invasive and more effective treatment in the future, when the prevalence of the disease is likely to reach its peak."

The researchers are the first in the world to test the blockade treatment on both proteins simultaneously, using human cells from pleural effusion fluid collected to relieve symptoms of breathlessness after patients have been diagnosed.

Associate Professor Klebe said the novel treatment would be tested on its ability to stop metastases, or cancer spread to other organs, as well as to ensure it does not kill healthy cells.

As it is difficult for clinicians to predict patient survival, Associate Professor Klebe said the two proteins could also be used as prognostic markers.

"We know that if a patient has high levels of the growth factor in their blood they will die quicker but we've now discovered that increased levels of the membrane protein are also associated with survival.

"So not only could we have a better way of treating mesothelioma, the two proteins allow us to give a more accurate prediction on how long people will survive."

Explore further: Novel blood-based protein signature determined for rare, aggressive lung cancer

Related Stories

Novel blood-based protein signature determined for rare, aggressive lung cancer

October 3, 2012
Researchers have discovered a panel of 13 blood proteins that may be effective biomarkers to detect malignant mesothelioma, according to a study published Oct. 3 in the open access journal PLOS ONE by Rachel Ostroff from ...

High levels of blood-based protein specific to mesothelioma

October 10, 2012
Researchers at NYU School of Medicine have discovered the protein product of a little-known gene may one day prove useful in identifying and monitoring the development of mesothelioma in early stages, when aggressive treatment ...

Renal cancer drug temsirolimus shows promise against mesothelioma

May 1, 2011
A drug commonly used to treat kidney cancer may increase the effectiveness of chemotherapy for mesothelioma, according to a study published in the May issue of the Journal of Thoracic Oncology.

E-nose detects malignant mesothelioma

August 2, 2012
Australian researchers have developed a breath test using an electronic nose to help diagnose malignant mesothelioma in its early stages, a potentially life-saving move.

Photodynamic therapy added to lung-sparing surgery improves survival for mesothelioma patients

May 30, 2012
(Medical Xpress) -- Among patients with malignant pleural mesothelioma, treatment with lung-sparing surgery in combination with photodynamic therapy (PDT) yielded unusually long survival rates, with median survival rates ...

Fasting time for tumour cells

March 15, 2013
(Medical Xpress)—Tumours need a steady supply of sufficient nutrients to be able to grow. In order to secure the nutrient availability, they secrete messenger compounds to stimulate neighbouring blood vessels to proliferate ...

Recommended for you

Physical activity could combat fatigue, cognitive decline in cancer survivors

July 25, 2017
A new study indicates that cancer patients and survivors have a ready weapon against fatigue and "chemo brain": a brisk walk.

Breaking the genetic resistance of lung cancer and melanoma

July 25, 2017
Researchers from Monash University and the Memorial Sloan Kettering Cancer Center (MSKCC, New York) have discovered why some cancers – particularly lung cancer and melanoma – are able to quickly develop deadly resistance ...

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

No dye: Cancer patients' gray hair darkened on immune drugs

July 21, 2017
Cancer patients' gray hair unexpectedly turned youthfully dark while taking novel drugs, and it has doctors scratching their heads.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.